The success of Sildenafil initially fueled a period of growth for the drug industry, but recent shifts present a complicated picture for those considering a stake. Generic alternatives are reducing earnings, and continued litigation add further complexity to the equation. While some companies may still see gains from related offerings, the broad… Read More